Immunome (Nasdaq:IMNM) - 주가, 뉴스 및 분석

IMNM 주식 개요

는 표적 암 치료제를 개발하는 생명공학 회사입니다. 자세한 내용

IMNM 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 65.1% 증가할 것으로 예상됩니다.

위험 분석

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

Immunome, Inc. 경쟁사

Capricor Therapeutics

NasdaqCM:CAPR

US$840.7m

Entrada Therapeutics

NasdaqGM:TRDA

US$674.1m

Verve Therapeutics

NasdaqGS:VERV

US$455.5m

Arcutis Biotherapeutics

NasdaqGS:ARQT

US$1.2b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Immunome
과거 주가
현재 주가	US$9.91
52주 최고치	US$30.96
52주 최저치	US$6.93
베타	1.82
11개월 변경	-19.73%
3개월 변경 사항	-26.79%
1년 변경 사항	23.97%
33년 변화	-42.41%
5년 변화	n/a
IPO 이후 변화	-26.36%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	IMNM	US Biotechs	US 마켓
7D	-23.7%	-10.9%	-2.2%
1Y	24.0%	13.9%	30.1%

수익률 대 산업: IMNM 지난 1년 동안 13.9 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: IMNM 지난 1년 동안 30.1 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is IMNM's price volatile compared to industry and market?
IMNM volatility
IMNM Average Weekly Movement	9.3%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.6%
10% least volatile stocks in US Market	3.1%

안정적인 주가: IMNM 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: IMNM 의 주간 변동성( 9% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2006	105	Clay Siegall	immunome.com

이뮤놈은 표적 암 치료제를 개발하는 생명공학 회사입니다. 이 회사의 임상 자산은 현재 데스모이드 종양 치료를 위한 임상 3상 시험에서 평가 중인 연구용 감마 분비 효소 억제제인 AL102와 티로신 키나제 유사 고아 수용체 1 수용체 및 항체-약물 접합체인 IM-1021, 섬유아세포 활성화 단백질 표적 방사선 리간드 치료제인 IM-3050, 항 IL-38 면역 치료제 후보인 IM-4320으로 구성되어 있습니다. 이뮤놈은 2006년에 설립되었으며 워싱턴주 보셀에 본사를 두고 있습니다.

Immunome, Inc. 기본 사항 요약

Immunome 의 수익과 매출은 시가총액과 어떻게 비교하나요?
IMNM 기본 통계
시가총액	US$695.32m
수익(TTM)	-US$305.35m
수익(TTM)	US$10.13m

61.0x

P/S 비율

-2.0x

P/E 비율

IMNM 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
IMNM 손익 계산서(TTM)
수익	US$10.13m
수익 비용	US$91.13m
총 이익	-US$81.00m
기타 비용	US$224.35m
수익	-US$305.35m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-4.89
총 마진	-799.64%
순이익 마진	-3,014.59%
부채/자본 비율	0%

IMNM 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

IMNM 주식 개요

보상

위험 분석

Immunome, Inc. 경쟁사

NasdaqCM:CAPR

US$840.7m

NasdaqGM:TRDA

US$674.1m

NasdaqGS:VERV

US$455.5m

NasdaqGS:ARQT

US$1.2b

가격 내역 및 성능

최근 뉴스 및 업데이트

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunome Presents Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome, Inc. Appoints Roee Shahar as Executive Vice President, Commercial

Executive VP of Operations notifies of intention to sell stock

Immunome, Inc. to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors At the European Society for Medical Oncology Congress 2024

Consensus revenue estimates increase by 21%, EPS downgraded

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunome Presents Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome, Inc. Appoints Roee Shahar as Executive Vice President, Commercial

Executive VP of Operations notifies of intention to sell stock

Immunome, Inc. to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors At the European Society for Medical Oncology Congress 2024

Consensus revenue estimates increase by 21%, EPS downgraded

Price target decreased by 8.7% to US$30.60

Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer

President recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 97%, revenue upgraded

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Consensus EPS estimates fall by 17%

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

New minor risk - Share price stability

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

Consensus EPS estimates upgraded to US$0.97 loss

Immunome: Why It Has Doubled Over The Last Month

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome, Inc. Announces Board Changes

Immunome, Inc. Announces Executive Changes, Effective January 2, 2024

Immunome, Inc. announced that it has received $124.722508 million in funding from Enavate Sciences, EcoR1 Capital, LLC, Redmile Group, LLC, Janus Henderson Group plc, Avidity Partners Management, L.P., Woodline Partners LP and other investors

Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors

Immunome Appoints Bob Lechleider as Chief Medical Officer

Less than half of directors are independent

New major risk - Shareholder dilution

Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others for $51.7 million.

Immunome, Inc. announced that it expects to receive $124.722508 million in funding

No longer forecast to breakeven

Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?

Immunome, Inc. Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$8.50

High number of new directors

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Forecast to breakeven in 2024

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

Immunome GAAP EPS of -$0.74

Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation

Immunome, Inc.’S Covid-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants in the Us, Ba.4/5 and Ba.2.12.1

Immunome gains 34% after preclinical data on COVID-19 antibody

Immunome, Inc. Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38

Immunome, Inc. Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

Immunome, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target increased to US$33.00

We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth

Immunome, Inc. Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in Vitro Live Virus Testing

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Expects IMM-BCP-01 Antibody Cocktail to Neutralize the SARS-CoV-2 Omicron Variant

Immunome Announces Submission of Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth